Targeting the KRAS protein has been one of cancer research’s toughest challenges of the last 40 years.1,2
Through the ongoing CodeBreaK clinical trials, Amgen is currently exploring the potential of KRASG12C inhibition across multiple tumor types with the KRASG12C mutation, with the goal of advancing care for seriously ill patients.
Learn more about how Amgen is pioneering the latest research in KRAS G12C.REFERENCES
- Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851.
- Fernandez-Medarde A, et al. Genes Cancer. 2011;2:344-358.